NEW YORK (TheStreet) -- ImmunoGen (IMGN - Get Report) stock is tumbling on Friday after the biotechnology company saw third-quarter losses gap wider than expected and as revenue fell short of analysts' estimates.
By midday, shares had dropped -7.2% to $12.80.
Over the three months to March, Waltham, Mass.-based ImmunoGen reported a net loss of 44 cents a share compared to losses of 2 cents a share in the year-ago quarter. Analysts surveyed by Thomson Reuters had forecast a net loss of 27 cents a share.Revenue tumbled to $6.88 million from $25 million a year earlier, missing estimates of $13.28 million. Must read: Warren Buffett's 10 Favorite Growth Stocks STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts